



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	136.31
Trade Time:	4:00 PM ET Jul 20, 2017
Change:	1.31 (0.970%)
Day Range	134.60 - 137.45
52-Week Range	96.93 - 136.12
Volume	3,856,925

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®] and ISTODAX[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 5, 2017
[Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers](#)

Jul 5, 2017
[Celgene Corporation to Announce Second Quarter 2017 Results on July 27, 2017](#)

Jun 22, 2017
[Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene's SHOW MORE OF YOU Campaign](#)

Jun 19, 2017
[Celgene Announces Clinical Data Evaluating Broad Range of Blood Cancers to Be Presented at EHA 2017](#)

Jun 17, 2017
[Updated Data from Phase IIIb MAGNIFY Study of REVLIMID \(lenalidomide\) and Rituximab Combination \(R2\) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma](#)

Upcoming Events [\[View all \]](#)

Jul 27, 2017 9:00 AM ET
[Celgene Corporation Q2 2017 Celgene Corp. Earnings Conference Call](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 10, 2017
[Annual Report \(10-K\)](#)

Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)

Apr 27, 2017
[Quarterly Report \(10-Q\)](#)

Oct 27, 2016
[Quarterly Report \(10-Q\)](#)

Jul 28, 2016
[Quarterly Report \(10-Q\)](#)